IASLC TTLC 2024 | Racial disparities in lung cancer biomarker testing and clinical trial recruitment

Debora Bruno, MD, Seidman Cancer Center, Cleveland, OH, comments on findings from an analysis of a database, which revealed low rates of next-generation sequencing (NGS) in patients with lung cancer. Testing rates were especially low in patients of color, where black patients with non-small cell lung cancer (NSCLC) were subsequently underrepresented in clinical trials. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.